Skip to Content
Be ready for a severe allergy emergency. Read more >>

Ketorolac ophthalmic Pregnancy and Breastfeeding Warnings

Ketorolac ophthalmic is also known as: Acular, Acular LS, Acular PF, Acuvail

Ketorolac ophthalmic Pregnancy Warnings

Avoid use during third trimester of pregnancy. Prior to third trimester: Use only if the potential benefit justifies the potential risk to the fetus. AU TGA pregnancy category: C US FDA pregnancy category: C (0.45% and 0.5% ophthalmic solutions); Not assigned (0.4% ophthalmic solution) Risk summary (0.4% ophthalmic solution): No data available on use of this drug in pregnant women to inform a drug-related risk.

Animal studies have revealed evidence of dystocia and increased pup mortality at oral doses of 1.5 mg/kg/day (about 40 times the typical human ophthalmic daily dose). Prostaglandin inhibitors used during late pregnancy have demonstrated adverse effects on the fetal cardiovascular system, including closure of the fetal ductus arteriosus. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

See references

Ketorolac ophthalmic Breastfeeding Warnings

Caution is recommended; according to some experts, use is not recommended. Excreted into human milk: Unknown Excreted into animal milk: Data not available Comments: -This drug is present in breast milk following oral administration. -Placing pressure over the tear duct by the corner of the eye for at least 1 minute and removing excess solution with an absorbent tissue substantially reduces the amount of drug that reaches breast milk after using eye drops.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Acular (ketorolac)." Allergan Inc, Irvine, CA.
  3. Cerner Multum, Inc. "Australian Product Information." O 0
  4. "Product Information. Acuvail (ketorolac ophthalmic)." Allergan Inc, Irvine, CA.
  5. "Product Information. Acular LS (ketorolac ophthalmic)." Allergan Inc, Irvine, CA.

References for breastfeeding information

  1. "Product Information. Acuvail (ketorolac ophthalmic)." Allergan Inc, Irvine, CA.
  2. "Product Information. Acular LS (ketorolac ophthalmic)." Allergan Inc, Irvine, CA.
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):
  4. "Product Information. Acular (ketorolac)." Allergan Inc, Irvine, CA.
  5. Cerner Multum, Inc. "Australian Product Information." O 0
  6. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide